Skip to main content
. 2018 Aug 28;8:12961. doi: 10.1038/s41598-018-31005-4

Figure 2.

Figure 2

Binding of human strains VP8* to HBGAs measured by saliva-based binding assay. VP8* proteins from vaccine strains (Rotarix (P[8]) and RotaTeq (P[8])), cell culture-adapted strains (Wa (P[8]) and DS-1 (P[4])) and three P[8] clinical strains (287, 183 and 134) were tested for binding to a panel of previously well-defined A, B, O, secretor and Lewis types saliva samples (SE = Secretor (FUT2+); se = non-secretor (FUT2); Le+ = Lewis positive (FUT3+); le = Lewis negative (FUT3); O, A and B = Blood group O, A and B). (a) The binding profile of VP8* proteins to HBGAs is identical for all the strains tested with a binding to mucins of SE/Le+ phenotypes only (SE/Le+ n = 32, SE/le n = 12, se/Le+ n = 11 and se/le n = 4). (b) Within the SE/Le+ group, ABO phenotype has an effect with a binding to saliva samples from blood group O ≥ A > B (O n = 12, A n = 12 and B n = 8). Mann-Whitney test was used to compare groups (***p < 0.001, **p < 0.01, *p < 0.05).